MedTrace Logo

Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey

NCT05765890 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 675

Last updated 2023-10-11

No results posted yet for this study

Summary

The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines.

This study is a cross-sectional design, conducted across 5 countries in Europe- France, Germany, Spain, United Kingdom (UK), Italy. Study participants, Hepatologists and other metabolically focused healthcare providers (HCPs), will be recruited to complete a 15 minute self-administered online survey.

Conditions

  • Non-alcoholic Steatohepatitis (MASH)
  • Non-alcoholic Fatty Liver Disease (MASLD)

Interventions

OTHER

No treatment given

No treatment given

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-24
Primary Completion
2023-09-12
Completion
2023-09-12

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05765890 on ClinicalTrials.gov